European Commission Expands Indication for PLAVIX(R) (clopidogrel bisulfate) Offering New Option for Patients With Most

    
    References:
    1. American Heart Association/American College of Cardiology Scientific
       Statement. New guidelines emphasize need for speed when chest pain
       strikes.
       http://www.americanheart.org/presenter.j....
       Accessed August 2006.
    2. Atherothrombosis.org. What is atherothrombosis?
       http://www.atherothrombosis.org/public/i....
       Accessed August, 2006.
    3. COMMIT (CIOpidogrel and Metoprolol in Myocardial Infarction Trial)
       collaborative group. Early intravenous then oral metoprolol in 45852
       patients with acute myocardial infarction randomised
       placebo-controlled trial. Lancet 2005; 366: 1622-32.
    4. American Heart Association. Heart Disease and Stroke Statistics
       2006 Update.
       http://circ.ahajournals.org/cgi/reprint/....
       Accessed August 2006.
    5. Steg GS, Goldberg RJ, et al. Baseline Characteristics, Management
       Practices, and In-Hospital Outcomes of Patients Hospitalized With
       Acute Coronary Syndromes in the Global Registry of Acute Coronary
       Events (GRACE). Am J Cardiol 2002;90: 358-363.
    6. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to
       aspirin and fibrinolytic therapy for myocardial infarction with
       ST-segment elevation. N Engl J Med 2005;352:1179-1189.
    7. IMS Health Acute Coronary Syndromes Analysis 2005.
    8. Viles-Gonzalez JF et al. Atherothrombosis: A widespread disease with
       unpredictable and life-threatening consequences. Eur Heart J 2004;
       25: 1197-1207.
    9. Data on file, sanofi-aventis.
    10. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial
        Investigators. N Engl J Med 2001;345:494-502.
    11. Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of Clopidogrel
        Versus Aspirin in Patients With Prior Cardiac Surgery. Circulation.
        2001;103:363-368.

Web site: http://www.bms.com

Brian Henry of Bristol-Myers Squibb, +33-1-58-83-69-38, brian.henry@bms.com; Salah Mahyaoui of sanofi-aventis, +33-1-53-77-40-31, salah.mahyaoui@sanofi-aventis.com